new concerns about using selegiline (Eldepryl) for patients with early Parkinson's disease

April 1996

There are new concerns about using selegiline (Eldepryl) for patients with early Parkinson's disease.

A surprising British study suggests that adding selegiline to levodopa therapy doesn't slow the progression of Parkinson's...and might increase mortality.

But tell patients not to panic...many experts dispute these findings and say the study was flawed. Most neurologists say that selegiline DOES help certain patients...by improving symptoms and having a levodopa-sparing effect.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote